EVAH

EVAH in its $20 million Series A financing round

Client

EVAH

Value

$20 million

Service

Emerging and High Growth Companies

Date Closed

Industry

Pharmaceuticals, Biotech & Life Sciences

Lead Office

Montréal

 

On September 22, 2021, EVAH announced its $20 million Series A financing round led by global investors from Canada, Europe and the United States. The $20 million funding includes $11.625 million with participation from Groupe Jafaco Gestion, Grupo Fuertes and M.R.Capital et Investissements and $4.95 million from the Québec Ministry of Economy and Innovation's BioMed Propulsion Program. The proceeds from the financing will be used to expand the company’s business and scientific activities in Québec and Prince Edward Island.

EVAH is a Canadian biotechnology company specializing in acquiring and developing technologies for animal health.

Osler, Hoskin & Harcourt LLP advised EVAH with a team consisting of Shahir Guindi, Liliana Korosi, Sarah Lazure and Asma Berrak (Corporate).